DEBIOPHARM-DEBIO0123-102
Phase I
OPEN TO ACCRUAL
A Phase 1, Dose-Finding Study of Debio 0123 as Monotherapy in Adult Patients with Advanced Solid Tumors, Followed by an Expansion Part to Assess Safety and Preliminary Anti-Tumor Activity
GOG-3082-ACRIVON-ACR-368-201
Phase I/II
OPEN TO ACCRUAL
A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status
GOG-3104-GILEAD-GS-US-682-6769
Phase III
OPEN TO ACCRUAL *
A Randomized, Open-Label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants with Endometrial Cancer Who Have Received Prior Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
HOFFMANN-BO41932-TAPISTRY
Phase II
OPEN TO ACCRUAL
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
IIT-GEORGE-I-PREDICT
Phase I/II
OPEN TO ACCRUAL
An Open-Label, Navigational Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy for Patients with Aggressive Malignancies and Poor Prognoses
NRG-GY028
Phase I/II
OPEN TO ACCRUAL *
A Phase IB and Randomized Phase II Trial of Megestrol Acetate with or without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial Cancer
TAKEDA-TAK-280-1501
Phase I/II
OPEN TO ACCRUAL
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients with Unresectable Locally Advanced or Metastatic Cancer
XILIO-XTX301-01-02-001
Phase I
OPEN TO ACCRUAL
A First-in-Human, Multicenter, Phase 1, Open-Label Study of XTX301 in Patients with Advanced Solid Tumors